Comparative analysis of oncologic outcomes for open vs. robot-assisted radical prostatectomy in high-risk prostate cancer
이동현, 최승권, 박진성, 심명선, 김아람, 이상미, 송채린, 안한중,
소속 상세정보
이동현 ( Lee Dong-Hyun )
University of Ulsan College of Medicine Asan Medical Center Department of Urology
최승권 ( Choi Seung-Kwon )
Kyung Hee University School of Medicine Department of Urology
박진성 ( Park Jin-Sung )
Eulji University School of Medicine Department of Urology
심명선 ( Shim Myung-Sun )
University of Ulsan College of Medicine Asan Medical Center Department of Urology
김아람 ( Kim A-Ram )
University of Ulsan College of Medicine Asan Medical Center Department of Urology
이상미 ( Lee Sang-Mi )
University of Ulsan College of Medicine Asan Medical Center Department of Urology
송채린 ( Song Che-Ryn )
University of Ulsan College of Medicine Asan Medical Center Department of Urology
안한중 ( Ahn Han-Jong )
University of Ulsan College of Medicine Asan Medical Center Department of Urology
KMID : 0358320150560080572
Abstract
Purpose: To evaluate the oncologic outcomes of robot-assisted radical prostatectomy (RARP) in high-risk prostate cancer (PCa), we compared the surgical margin status and biochemical recurrence-free survival (BCRFS) rates between retropubic radical prostatectomy (RRP) and RARP.
Materials and Methods: A comparative analysis was conducted of high-risk PCa patients who underwent RRP or RARP by a single surgeon from 2007 to 2013. High-risk PCa was defined as clinical stage≥T3a, biopsy Gleason score 8-10, or prostate-specific antigen>20 ng/mL. Propensity score matching was performed to minimize selection bias, and all possible preoperative and postoperative confounders were matched. A Kaplan-Meier analysis was performed to assess the 5-year BCRFS, and Cox regression models were used to evaluate the effect of the surgical approach on biochemical recurrence.
Results: A total of 356 high-risk PCa patients (106 [29.8%] RRP and 250 [70.2%] RARP) were included in the final cohort analyzed. Before adjustment, the mean percentage of positive cores on biopsy and pathologic stage were poorer for RRP versus RARP (p=0.036 vs. p=0.054, respectively). The unadjusted 5-year BCRFS rates were better for RARP than for RRP (RRP vs. RARP: 48.1% vs. 64.4%, p=0.021). After adjustment for preoperative variables, the 5-year BCRFS rates were similar between RRP and RARP patients (48.5% vs. 59.6%, p=0.131). The surgical approach did not predict biochemical recurrence in multivariate analysis.
Conclusions: Five-year BCRFS rates of RARP are comparable to RRP in high-risk PCa. RARP is a feasible treatment option for high-risk PCa.
키워드
Prostatic neoplasms ; Prostatectomy ; Treatment outcome
원문 및 링크아웃 정보
등재저널 정보